Market Overview

Journal Publishes Grafix Clinical Study for Chronic Wounds

Osiris
Therapeutics (NASDAQ: OSIR) announced today that data, published in Ostomy
Wound Management, shows that the use of Grafix® on a variety of
chronic wounds resulted in an overall closure rate of 76% by 12 weeks,
including 68% of Venous Leg Ulcers (VLUs) and 85% of Diabetic Foot
Ulcers (DFUs) treated. The publication is available in the December 2013
issue of Ostomy Wound Management and on its website.

“The overall healing rate of 76% among recalcitrant wounds demonstrates
the profound effect Grafix had on my patients,” said Dr. Matthew
Regulski, lead author and Medical Director of

See full press release

Posted-In: News Guidance Asset Sales Management M&A Global

 

Most Popular

Related Articles (OSIR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free